Medpace (NASDAQ:MEDP) Trading Up 1.6%

Medpace Holdings, Inc. (NASDAQ:MEDP)’s stock price traded up 1.6% on Monday . The stock traded as high as $403.12 and last traded at $398.85. 61,611 shares traded hands during trading, a decline of 75% from the average session volume of 247,262 shares. The stock had previously closed at $392.57.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Robert W. Baird raised their price objective on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft assumed coverage on Medpace in a research note on Monday, March 18th. They set a “hold” rating and a $395.00 price objective on the stock. Guggenheim raised their price objective on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday, April 23rd. Finally, UBS Group upgraded Medpace from a “neutral” rating to a “buy” rating and raised their price objective for the company from $282.00 to $452.00 in a research note on Thursday, February 15th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Medpace currently has a consensus rating of “Moderate Buy” and a consensus price target of $443.00.

Medpace Stock Performance

The company has a market capitalization of $12.41 billion, a P/E ratio of 40.73, a PEG ratio of 1.95 and a beta of 1.40. The stock has a 50 day moving average price of $398.08 and a 200 day moving average price of $331.78.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The company had revenue of $511.00 million for the quarter, compared to analysts’ expectations of $512.39 million. During the same period in the previous year, the business posted $2.27 EPS. The business’s revenue for the quarter was up 17.7% compared to the same quarter last year. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 11.23 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Susan E. Burwig sold 102 shares of Medpace stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the sale, the vice president now owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Medpace news, CEO August J. Troendle sold 100,000 shares of Medpace stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at approximately $1,995,940,186.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Susan E. Burwig sold 102 shares of Medpace stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the transaction, the vice president now directly owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The disclosure for this sale can be found here. In the last 90 days, insiders sold 204,442 shares of company stock valued at $82,702,867. 20.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of MEDP. Wellington Management Group LLP grew its holdings in shares of Medpace by 312.6% during the third quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock worth $102,013,000 after purchasing an additional 319,210 shares in the last quarter. TD Asset Management Inc lifted its position in Medpace by 195.2% in the 4th quarter. TD Asset Management Inc now owns 467,041 shares of the company’s stock worth $143,162,000 after buying an additional 308,816 shares during the last quarter. Invesco Ltd. lifted its position in Medpace by 67.6% in the 3rd quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock worth $148,159,000 after buying an additional 246,775 shares during the last quarter. Findlay Park Partners LLP bought a new stake in Medpace in the 1st quarter worth approximately $90,247,000. Finally, Norges Bank bought a new stake in Medpace in the 4th quarter worth approximately $59,163,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.